Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Aroosha Sarrafi tells Health her story of getting diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), a ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

This local sensation mashes up pop and rock hits with a full brass section, turning every show into a high-energy singalong.

Because nothing tests your patience — or your posture — like youth sports season. NEW YORK , NY May 6, 2025 With Mother's Day ...

Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Target RWE, a leader in modern clinical evidence generation for complex diseases, today announced its presentations and strategic contributions at the EASL Congress 2025 in Amsterdam, Netherlands.

It took a month, but this is the Phillies lineup that was advertised. They pounded the Rays on Wednesday to with their fourth ...